BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy

[PR Newswire] – RALEIGH, N.C., May 6, 2014 /PRNewswire/ — BioDelivery Sciences International, Inc. (BDSI) announced that it has randomized more than half of the planned number of patients required for its ongoing initial Phase 3 study of Clonidine Topic more

View todays social media effects on BDSI

View the latest stocks trending across Twitter. Click to view dashboard

See who BioDelivery is hiring next, click here to view